The utility of insulin glargine in the treatment of diabetes mellitus

Pharmacotherapy

Volumn 24, Issue 6, 2004, Pages 736-742

  Stroup, Jeffrey ^a   Kane, Michael P ^b   Busch, Robert S ^c   Bakst, Gary ^c   Hamilton, Robert A ^b  

^a UNIVERSITY OF OKLAHOMA   (United States)

^b ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^c Endocrine Group   (United States)

Author keywords

Diabetes mellitus; Glycemic control; Hemoglobin A1c; Hyperglycemia; Hypoglycemia; Insulin glargine; NPH insulin

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; GLIPIZIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN GLARGINE; ISOPHANE INSULIN; MEGLITINIDE; METFORMIN; PIOGLITAZONE; REPAGLINIDE; SHORT ACTING DRUG; SULFONYLUREA;

ADULT; AGED; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; DRUG USE; ENDOCRINOLOGY; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; RETROSPECTIVE STUDY; SIDE EFFECT; STATISTICAL SIGNIFICANCE;

ADULT; AGED; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; ENDOCRINOLOGY; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; MALE; MIDDLE AGED; OBESITY; PRIVATE PRACTICE; RETROSPECTIVE STUDIES;

EID: 2942616447     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.24.8.736.36064     Document Type: Article

References (25)

1. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103-17.
2. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
3. Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 40). JAMA 1999;281:2005-12.
4. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999;131:281-303.
5. Binder C, Lauritzen T, Faber O, et al. Insulin pharmacokinetics. Diabetes Care 1984;3:188-99.
6. Mecklenburg RS, Benson EA, Benson JW Jr, et al. Long-term metabolic control with insulin pump therapy. N Engl J Med 1985;313:465-8.
7. Bode BW, Steed RD, Davidson PC. Reduction in severe hypoglycemia with long-term continuous subcutaneous insulin infusion in type I diabetes. Diabetes Care 1996;19:324-7.
8. Boland EA, Grey M, Oesterle A, Fredrickson L, Tamborlane WV. Continuous subcutaneous insulin infusion: a new way to lower risk of severe hypoglycemia, improve metabolic control, and enhance coping in adolescents with type 1 diabetes. Diabetes Care 1999;22:1779-84.
9. Barnett AH, Owens DR. Insulin analogues. Lancet 1997;349:47-51.
10. Bolli GB, DiMarchi RD, Park GD, et al. Insulin analogues and their potential in the management of diabetes mellitus. Diabetologia 1999;42:1151-67.
11. Aventis Pharmaceuticals, Inc. Lantus (glargine) package insert. Bridgewater, NJ; 2000.
12. Lepore M, Pampanelli S, Fanelli C, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000;49:2142-8.
13. Ratner RE, Hirsch IB, Neifing JL, et al. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. Diabetes Care 2000;23:639-43.
14. Raskin P, Klaff L, Bergenstal R, et al. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. Diabetes Care 2000;23:1666-71.
15. Rosenstock J, Schwartz SL, Clarke CM Jr, et al. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 2001;24:631-6.
16. Yki-Jarvinen H, Dressler A, Ziemen M, et al. Less nocturnal hypoglycemia with better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care 2000;23:1130-6.
17. Riddle M, Rosenstock J, Gerich J, and the Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26:3080-6.
18. Hamann A, Matthaei S, Rosak C, Silvestre L, for the HOE 901/4007 Study Group. A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes. Diabetes Care 2003;26:1738-44.
19. Fritsche A, Schweitzer MA, Haring HU, and the 4001 Study Group. Glimepiride combined with morning insulin glargine, bedtime neutral protamine Hagedorn, or bedtime insulin glargine in patients with type 2 diabetes. Ann Intern Med 2003;138:952-9.
20. Rossetti P, Pampanelli S, Fanelli C, et al. Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime. Diabetes Care 2003;26:1490-6.
21. Benedetti M, Humburg E, Dressler A, Ziemen M, for the 3002 Study Group. A one-year, randomized, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Hormone Metab Res 2003;35:189-96.
22. Schreiber S, Rubmann A. Improved metabolic control in patients with type 1 and type 2 diabetes following the initiation/switching to insulin glargine in clinical practice. Presented as a poster at the 62nd scientific sessions of the American Diabetes Association, San Francisco, CA, June 14-18, 2002.
23. Feinstein AR. An additional basic science for clinical medicine. 11: the limitations of randomized trials. Ann Intern Med 1983;99:544-50.
24. Nathan DM, Lachin J, Cleary P, et al. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med 2003;348:2294-303.
25. Gaede P, Vedel P, Larsen M, et al. Multifactorial interventions and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383-93.